Enterocyte-Like Cell Differentiation for Stable Drug Metabolism Testing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for inducing differentiation from pluripotent stem cells into enterocyte-like cells face challenges such as low expression of drug metabolic enzymes and transporters, species differences, and individual variability, making it difficult to obtain cells suitable for stable pharmacokinetic evaluations.
Innovation Solution
A method involving the induction of pluripotent stem cells into definitive endoderm cells using CHIR99021, followed by intestinal progenitor cells with specific culture conditions, and subsequent culture in organoid or two-dimensional systems to enhance the expression of drug metabolic enzymes and transporters.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional methods are used to induce differentiation from pluripotent stem cells into enterocyte-like cells, then cell production is achieved, but the expression levels of drug metabolic enzymes and transporters remain extremely low
Solution Approach 1:
The patent applies parameter changes by modifying the differentiation protocol parameters: using specific small molecule inhibitors (CHIR99031 at 3 μM, PD0325901 at 1 μM, LY3035113 at 1 μM) added at defined time points during differentiation, and optimizing culture conditions (organoid culture vs. monolayer culture) to achieve high expression levels of drug metabolic enzymes and transporters in enterocyte-like cells derived from pluripotent stem cells
2Reliability
If human primary enterocytes are used for evaluation, then human-specific pharmacokinetic data is obtained, but individual variability and short culture lifespan are problems
Solution Approach 1:
The patent uses copying by creating enterocyte-like cells that replicate the functional characteristics of human primary enterocytes through controlled differentiation of pluripotent stem cells. These copied cells express human-specific drug metabolic enzymes and transporters with high fidelity while overcoming the limitations of primary cells, enabling long-term stable culture for pharmacokinetic evaluation
3Ease of manufacture
If Caco-2 cells are used for in vitro evaluation, then cell culture is feasible, but species differences and low expression of drug transporters and metabolic enzymes occur
Solution Approach 1:
The patent extracts the essential functional characteristics of human enterocytes (expression of human-specific drug metabolic enzymes and transporters) from primary human enterocytes and transfers them into pluripotent stem cell-derived enterocyte-like cells. This extraction of key functional properties eliminates species differences while maintaining human-specific pharmacokinetic evaluation accuracy
4Productivity
If conventional differentiation methods are used, then enterocyte-like cells are produced, but the cells cannot be stably tested for drug metabolism and permeability
Solution Approach 1:
The patent applies preliminary action by pre-differentiating pluripotent stem cells into enterocyte-like cells with high expression levels of drug metabolic enzymes and transporters using optimized protocols (with CHIR99031, PD0325901, and LY3035113) before conducting pharmacokinetic evaluations. This preliminary optimization ensures that the cells are properly prepared and stable for reliable drug metabolism and permeability testing
Data Source
Figure 1
Figure 2(1)~2(2)
Figure 3(1)~3(3)
AI summary
While studies have been made on a method of selectively inducing differentiation from pluripotent stem cells into enterocyte-like cells, provided is an excellent and high-functionality enterocyte-like cell population that can be stably tested for multi-drug metabolism and permeability, and also provided an efficient method of producing cells. The method of inducing differentiation from pluripotent stem cells into enterocyte-like cells includes the following steps (1) and (2): (1) a step of inducing differentiation from pluripotent stem cells into definitive endoderm cells; and (2) a step of culturing the definitive endoderm cells in a system containing CHIR99021, followed by induction of differentiation into intestinal progenitor cells. A cell population of enterocyte-like cells is more effectively obtained by seeding and culturing enterocyte-like cells produced by the method of inducing differentiation, in a base material for organoid production or a base material for two-dimensional culture.